7 Cheap Pharmaceutical Stocks to Buy According to Hedge Funds
According to research, the U.S.
Zoetis Inc. (ZTS)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Diamond Hill Capital Ric Dillon | 3,158,638 | $397,419,833 | +18% | 2.04% |
| 2. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 3,038,437 | $382,296,143 | +13% | 0.22% |
| 3. | Impax Asset Management Ian Simm | 1,577,364 | $198,464,030 | -7% | 1.24% |
| 4. | Squarepoint Ops LLC Maxime Fortin (Cio) | 807,229 | $101,565,553 | +10% | 0.11% |
| 5. | Renaissance Technologies Jim Simons | 424,600 | $53,423,172 | +66% | 0.08% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $165.48 | 2,100 | $347,508.00 | 7,590 | 2021-02-19 | Filing | |
| $164.89 | 2,900 | $478,181.00 | 5,490 | 2021-02-19 | Filing | |
| $163.80 | 2,590 | $424,242.00 | 2,590 | 2021-02-19 | Filing | |
| $74.56 | 10 | $745.60 | 17 | 2018-01-11 | Filing | |
| $50.31 | 7 | $352.17 | 7 | 2016-10-14 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $170.00 | 652 | $110,840.00 | 15,129 | 2025-06-03 | Filing | |
| $170.00 | 326 | $55,420.00 | 15,781 | 2025-03-10 | Filing | |
| $166.14 | 1,210 | $201,029.40 | 11,245 | 2025-03-11 | Filing | |
| $156.68 | 382 | $59,852.26 | 94,194 | 2025-02-19 | Filing | |
| $171.18 | 326 | $55,804.68 | 16,107 | 2025-02-11 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 47,780,974 | $6,011,802,148 | 0.09% | |
| 2. | 37,350,823 | $4,699,480,504 | 0.08% | |
| 3. | 19,796,891 | $2,490,844,826 | 0.08% | |
| 4. | 15,892,903 | $1,999,645,056 | 1.57% | |
| 5. | 15,465,506 | $1,945,870,582 | 0.12% |
News See All
Zoetis Inc. (NYSE:ZTS) Q4 2025 Earnings Call Transcript
Operator: Thank you for your continued patience. Your meeting will begin shortly. If you need assistance at any time, please press 0, and a member of our team will be happy to help.
Pelican Bay Capital Management Bets on Zoetis (ZTS) to Capitalize on Expanding Pet Care Market
Pelican Bay Capital Management (PBCM), an investment management company, released its fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Zoetis Inc. (ZTS): A Bull Case Theory
We came across a bullish thesis on Zoetis Inc. on r/valueinvesting by ahlornjtvn139. In this article, we will summarize the bulls’ thesis on ZTS.
Zoetis (ZTS) Traded Lower Due to Reduced 2026 Outlook
Diamond Hill Capital, an investment management company, released its “Large Cap Fund” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Zoetis Inc. (ZTS) Sees Mixed Analyst Sentiment as Targets Are Trimmed
Zoetis Inc. (NYSE:ZTS) is among the most profitable healthcare stocks to buy.
10 Most Profitable Healthcare Stocks to Buy
By far, the healthcare sector remains among the most resilient and profitable in global equity markets.
Piper Sandler Flags Near-Term Uncertainty for Zoetis (ZTS) Despite Long-Term Appeal
On January 22, Piper Sandler downgraded Zoetis Inc. (NYSE:ZTS) to Neutral from Overweight. It also slashed its price target to $135 from $190.
12 Most Profitable Dividend Stocks to Buy in 2026
Savita Subramanian, the firm’s head of US equity and quant strategy, pointed to a familiar timing pattern. Dividend growth typically trails earnings growth by roughly three quarters.
Zoetis (ZTS): Harnessing Growth with Minimum Rivalry
Fundsmith, an investment management firm based in London, has released its annual 2025 investor letter for its “Fundsmith Equity Fund.” A copy of the letter can be downloaded here.
Hedge Fund Resource Center Billionaire Hedge Funds
